CELLIBRIUM BIOSCIENCES
Live / Allowed — Notice of allowance issued (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99310483
- Mark type
- Stylized text
- Filed
- 30 Jul 2025
- Published for opposition
- 13 Jan 2026
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurological diseases and neurodegenerative diseases; pharmaceutical preparations, namely, preparations for use in the treatment of Amyotrophic Lateral Sclerosis (ALS); pharmaceutical preparations, namely, B cell therapies for the treatment of neuroinflammation and immune dysregulation; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for the treatment of autoimmune diseases and traumatic brain injuries
- Class 042 — Scientific and technological services: Pharmaceutical research and development; research and development services in the field of cell therapy
Owner
- Cellibrium Biosciences, Inc., East Walpole, MA, US
- Cellibrium Biosciences, Inc., East Walpole, MA, US
Prosecution history
- 10 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Jan 2026 — PUBLISHED FOR OPPOSITION
- 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Dec 2025 — EXAMINER'S AMENDMENT ENTERED
- 17 Dec 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 17 Dec 2025 — EXAMINERS AMENDMENT E-MAILED
- 17 Dec 2025 — EXAMINERS AMENDMENT -WRITTEN
- 15 Dec 2025 — ASSIGNED TO EXAMINER
- 07 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Jul 2025 — APPLICATION FILING RECEIPT MAILED
- 30 Jul 2025 — NEW APPLICATION ENTERED